Loading...
XSHE
300357
Market cap1.77bUSD
Jul 10, Last price  
23.63CNY
1D
2.78%
1Q
-9.91%
Jan 2017
-32.52%
IPO
-54.91%
Name

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300357 chart
P/E
32.48
P/S
11.65
EPS
0.73
Div Yield, %
0.96%
Shrs. gr., 5y
Rev. gr., 5y
10.80%
Revenues
1.06b
+14.81%
37,407,15959,327,652103,176,299147,517,280193,609,754239,511,105267,105,585312,085,773385,576,841500,744,691639,352,852636,208,242807,691,605896,016,141848,190,443925,394,5241,062,404,471
Net income
381m
+19.86%
10,513,19318,405,87937,264,72953,773,77470,564,34999,554,761117,820,026129,200,977186,103,952232,884,099298,296,584278,447,288337,991,287348,773,476310,184,881317,822,382380,940,984
CFO
423m
+61.25%
12,628,50014,537,87119,149,70341,166,42658,303,54083,703,086114,820,239122,772,455159,134,139206,452,525232,925,579256,221,705360,575,120360,279,064388,318,565262,440,005423,195,746
Dividend
Jan 20, 20260.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. operates as a biopharmaceutical enterprise, primarily engaged in the discovery, development, production, and sale of medicinal products. The company's core focus is on pharmaceuticals designed for the diagnosis and management of allergic conditions, which it supplies to both the Chinese domestic market and international clientele. Additionally, its portfolio encompasses various skincare lines and stem cell-related solutions. The firm's main offices are located in Huzhou, China.
IPO date
Jan 21, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT